Fig. 3 | Hypertension Research

Fig. 3

From: Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers

Fig. 3

Baxdrostat Does Not Have a Significant Effect on Plasma Cortisol Levels. Estimated percentage change from baseline (day −1) in plasma cortisol (total) area under the pharmacodynamic effect-time curve from time 0 to 12 h postdose on day 1 and day 10. Data are least squares mean and 90% confidence intervals. AUC indicates area under the curve

Back to article page